Unavailable
Unavailable
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/25/2026 | $60.00 | Outperform | Oppenheimer |
| 2/18/2026 | $62.00 | Hold → Buy | Jefferies |
| 1/27/2026 | $73.00 | Overweight | Piper Sandler |
| 12/5/2025 | $12.00 | Underweight → Equal-Weight | Morgan Stanley |
| 10/22/2025 | $10.00 | Neutral → Buy | Citigroup |
| 2/28/2025 | Mkt Perform | William Blair | |
| 12/10/2024 | $40.00 → $5.00 | Overweight → Underweight | Morgan Stanley |
| 12/9/2024 | $42.00 → $7.00 | Buy → Hold | Jefferies |
Oppenheimer initiated coverage of BioAge Labs with a rating of Outperform and set a new price target of $60.00
Jefferies upgraded BioAge Labs from Hold to Buy and set a new price target of $62.00
Piper Sandler initiated coverage of BioAge Labs with a rating of Overweight and set a new price target of $73.00
4/A - BioAge Labs, Inc. (0001709941) (Issuer)
4 - BioAge Labs, Inc. (0001709941) (Issuer)
4 - BioAge Labs, Inc. (0001709941) (Issuer)
10-K - BioAge Labs, Inc. (0001709941) (Filer)
8-K - BioAge Labs, Inc. (0001709941) (Filer)
144 - BioAge Labs, Inc. (0001709941) (Subject)
Positive interim Phase 1 data for BGE-102, a potent, structurally novel, orally available, brain-penetrant small-molecule NLRP3 inhibitor, demonstrating potential best-in-class reductions in inflammatory biomarkers of cardiovascular risk; Phase 2a proof-of-concept trial planned to initiate in 1H 2026 Indication expansion for BGE-102 into ophthalmology; Phase 1b/2a proof-of-concept trial in diabetic macular edema planned to initiate mid-2026 Completed upsized follow-on public offering of $132.3 million with full exercise of the underwriters' overallotment option in February 2026 EMERYVILLE, Calif., March 24, 2026 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. ("BioAge", "the Company"), a cl
STOCKHOLM, March 23, 2026 /PRNewswire/ -- BioArctic's AB (publ) (NASDAQ:BIOA) partner Eisai presented new data at the 2026 International Conference on Alzheimer's and Parkinson's Diseases and related neurological disorders (AD/PD™), held in Copenhagen, Denmark March 17-21. BioArctic also held an oral presentation on lecanemab and a poster presentation relating to exidavnemab. Eisai presented new real-world findings from an analysis of long-term treatment persistence among early Alzheimer's disease patients in the United States receiving intravenous (IV) lecanemab. Based on data from the PurpleLab®[1] claims database, the analysis showed that most patients continued lecanemab therapy after
EMERYVILLE, Calif., Feb. 19, 2026 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (NASDAQ:BIOA) ("BioAge", "the Company"), a clinical-stage biotechnology company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging, today announced that the Company will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference taking place February 25-26, 2026. Kristen Fortney, PhD, CEO and co-founder, is scheduled to participate in a fireside chat on Thursday, February 26 from 10:40 AM to 11:05 AM ET. Fortney and Dov Goldstein, MD, CFO, will participate in one-on-one meetings. To access the live webcast of the presentation, register here. Replay
4 - BioAge Labs, Inc. (0001709941) (Issuer)
4 - BioAge Labs, Inc. (0001709941) (Issuer)
4 - BioAge Labs, Inc. (0001709941) (Issuer)
SC 13G - BioAge Labs, Inc. (0001709941) (Subject)
SC 13G - BioAge Labs, Inc. (0001709941) (Subject)
SC 13D - BioAge Labs, Inc. (0001709941) (Subject)